Account
Inquiry
Actually went with the Tirzepatide 15mg vials for our metabolic study pipeline—purity is listed at ≥99.9% by HPLC, which is better than reagent grade for this kind of work, and teh molecular weight of 4813 g/mol checks out against reference data.
We've got a batch of researchers looking at GLP-1 analog pathways, and this is pretty much the standard for in vitro glucose regulation work now, though it's definitely not suited for any in vivo application given the research-grade limitation.
The comes in 15mg per vial, 10, and storage is straightforward at 2-8°C protected from light—most buyers go with the boxed format for consistency across assays.
For EU customs clearance we needed the CAS number 2023788-19-2 on the invoice along with the COA, and the suppiler confirmed they include all standdard import docs (usually a TDS and SDS), so we shouldn't hit delays at the border.
Lead time is roughly 20 days or so form order, but we usually have stock in their EU warhouse so it might be faster—confirm that before you schedule the study start date.
One thing that caught me: the molecular formula C225H348N48O68 is pretty massive, so make sure your reconstitution buffer calculations account for that molarity—it's easy to underdose if you're used to smaller peptides.
We typically require a minimum of 1 box (10 vials) for first-time orders, but we can discuss smaller quantities if you're just starting out and need to test the product.
For in-stock Tirzepatide, we ship within 2-3 business days. If we need to manufacture a fresh batch, expect 7-10 business days, depending on your location.
Yes, we include a COA with every batch showing ≥99.9% purity by HPLC. Just request it when you order, and we'll send it along with the shipment.
Keep the vials refrigerated at 2-8°C and away from light. Once reconstituted, use it within a few days and don't freeze it.
We can do custom labels for bulk orders, but for standard 10-vial boxes, we keep the generic research-grade packaging. Just let us know your needs before ordering.
